Humoral Immune Response to COVID-19 Vaccines in Hematologic Malignancies

Data gathered in this study included: age, race, ethnicity, COVID-19 mRNA vaccine type, COVID-19 infection history prior to 3V of COVID-19 vaccine, days between the second and third dose of COVID-19 vaccine, HM diagnosis, up to four SARS-CoV-2 IgG antibodies results between 28 August 2021 and 31 January 2022, and days between the third dose of COVID-19 vaccine and each IgG result. Age values below 90 were collected as continuous and “Age 90 or older” was recoded as 90. Sex included male and female. Race was collapsed into White, Black, Asian/Pacific Islander, and multi-racial (two or more races). Ethnicity included Hispanic/Latino and non-Hispanic/Latino. Unknown values for Race and Ethnicity were removed from the analysis. COVID-19 mRNA vaccine type included Pfizer-BioNTech and Moderna. Days between vaccine doses were collected as continuous. COVID-19 infection history included all EMR-documented positive SARS-CoV-2 PCR test results for COVID-19 infection. IgG index level values “<0.50” and “>100.00” were recoded to 0.50 and 100.00, respectively.
Diagnosis was collapsed into lymphoid leukemia, non-Hodgkin lymphoma (NHL), multiple myeloma and other plasma cell neoplasms, Hodgkin lymphoma, myeloid leukemia, “Other,” and multiple conditions (Table 1).